Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas.
Williams SR, Juratli TA, Castro BA, Lazaro TT, Gill CM, Nayyar N, Strickland MR, Babinski M, Johnstone SE, Frosch MP, Silverman IM, Ely HA, Kaplan AB, D'Andrea MR, Bihun IV, Hoang K, Batchelor E, Christiansen J, Cahill DP, Barker FG 2nd, Brastianos PK. Williams SR, et al. J Neurol Surg B Skull Base. 2019 Dec;80(6):562-567. doi: 10.1055/s-0038-1676821. Epub 2019 Jan 10. J Neurol Surg B Skull Base. 2019. PMID: 31750041 Free PMC article.
Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas.
Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, Williams EA, Martinez-Lage M, Soucek S, Robel K, Penson T, Krause M, Appold S, Meinhardt M, Pinzer T, Miller JJ, Krex D, Ely HA, Silverman IM, Christiansen J, Schackert G, Wakimoto H, Kirsch M, Brastianos PK, Cahill DP. Juratli TA, et al. Oncotarget. 2017 Nov 24;8(65):109228-109237. doi: 10.18632/oncotarget.22650. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312603 Free PMC article.
DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.
Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG 2nd, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK. Juratli TA, et al. Acta Neuropathol. 2018 Nov;136(5):779-792. doi: 10.1007/s00401-018-1899-7. Epub 2018 Aug 19. Acta Neuropathol. 2018. PMID: 30123936
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M. Subbiah V, et al. Among authors: silverman im. Ann Oncol. 2022 May;33(5):522-533. doi: 10.1016/j.annonc.2022.02.001. Epub 2022 Feb 14. Ann Oncol. 2022. PMID: 35176457 Free article. Clinical Trial.
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K, Necchi A, Burn TC, Gjoerup O, Greenstein R, Krook M, López JA, Montesion M, Nimeiri H, Parikh AR, Roychowdhury S, Schwemmers S, Silverman IM, Vogel A. Murugesan K, et al. Among authors: silverman im. ESMO Open. 2022 Dec;7(6):100641. doi: 10.1016/j.esmoop.2022.100641. Epub 2022 Nov 30. ESMO Open. 2022. PMID: 36462464 Free PMC article.
ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).
Fontana E, Rosen E, Lee EK, Højgaard M, Mettu NB, Lheureux S, Carneiro BA, Cote GM, Carter L, Plummer R, Mahalingam D, Fretland AJ, Schonhoft JD, Silverman IM, Wainszelbaum M, Xu Y, Ulanet D, Koehler M, Yap TA. Fontana E, et al. Among authors: silverman im. J Natl Cancer Inst. 2024 May 6:djae098. doi: 10.1093/jnci/djae098. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 38710487
Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas.
Nakazawa MS, Silverman IM, Rimkunas V, Veloso A, Glodzik D, Johnson A, Ohsumi TK, Patel SR, Conley AP, Roland CL, Soliman PT, Beird HC, Wu CC, Ingram DR, Lazcano R, Song D, Wani KM, Lazar AJ, Yap TA, Wang WL, Livingston JA. Nakazawa MS, et al. Among authors: silverman im. Mol Cancer Ther. 2024 Apr 2. doi: 10.1158/1535-7163.MCT-23-0761. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38561019
164 results